Prelude Capital Management, LLC Atara Biotherapeutics, Inc. Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $337,844 - $676,089	-40,029 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $588,426 - $796,176	40,029 New	40,029 $631,000
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $956,610 - $1.43 Million	-79,784 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $116,551 - $149,916	-9,042 Reduced 10.18%	79,784 $1.24 Million
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $1.24 Million - $1.84 Million	88,826 New	88,826 $1.28 Million
Q4 2020 Feb 16, 2021	SELL	$12.67 - $26.23 $1,267 - $2,623	-100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $1,192 - $1,587	100 New	100 $1,000
Q4 2018 Feb 14, 2019	SELL	$30.9 - $42.97 $68,845 - $95,737	-2,228 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$35.05 - $43.5 $78,091 - $96,918	2,228 New	2,228 $92,000
Q4 2017 Feb 14, 2018	SELL	$13.2 - $18.1 $174,570 - $239,372	-13,225 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$13.25 - $17.05 $175,231 - $225,486	13,225	13,225 $219,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.59B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.